atopic dermatitis
Dermatology · 2006–2026
23decisions
9medicines
20carried consumer input
703individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nemolizumab Treatment of patients aged 12 years or older with chronic severe atopic dermatitis affecting the whole body, face, and/or hands who are inadequately controlled… | Mar 2026 | Recommended with restriction | no section in document |
| nemolizumab Treatment of chronic severe atopic dermatitis affecting the whole body, face, and/or hands in patients aged 12 years or older who are inadequately controlled… | Jul 2025 | Not recommended | input received Eczema Support Australia · Anaphylaxis Australia · National Allergy Council |
| tacrolimus Moderate to severe atopic dermatitis in patients aged 16 years and older who have failed to achieve satisfactory disease control with topical corticosteroids… | Jul 2025 | Recommended with restriction | input received |
| tacrolimus Treatment of moderate to severe atopic dermatitis in patients aged 16 years and older who have failed to achieve satisfactory disease control with topical… | Jul 2025 | Recommended with restriction | input received |
| dupilumab Treatment of severe atopic dermatitis in patients aged less than 12 years, and uncontrolled severe asthma in patients aged 6 to 11 years. | Mar 2025 | Recommended with restriction | input received |
| dupilumab Severe atopic dermatitis in patients aged 12 years and older. | Jul 2024 | Not recommended | input received |
| lebrikizumab Treatment of severe atopic dermatitis (affecting the whole body or the face and/or hands) in patients aged 12 years or older who are inadequately controlled on… | Mar 2024 | Recommended with restriction | 5 individuals Eczema Association · Eczema Support Australia · Anaphylaxis Australia · National Allergy Council |
| abrocitinib Treatment of adult patients with chronic severe atopic dermatitis who are unable to achieve disease control with daily use of topical treatments for at least… | Nov 2024 | Recommended with restriction | 4 individuals Eczema Support Australia |
| dupilumab Severe atopic dermatitis in patients aged 12 years or older. This resubmission addressed revised utilisation estimates and proposed a revised risk sharing… | Jul 2023 | Noted | input received |
| dupilumab Treatment of severe atopic dermatitis in patients aged 12 years and older. | Nov 2023 | Noted | 1 individuals |
| dupilumab Severe chronic atopic dermatitis in patients aged 12 years or older. | Jul 2022 | Noted | input received Anaphylaxis Australia · Eczema Support Australia |
| dupilumab Treatment of children aged 6 to 11 years with severe atopic dermatitis who have had an inadequate response to topical therapies. | Mar 2022 | Recommended | 60 individuals Anaphylaxis Australia · Eczema Support Australia |
| dupilumab Chronic severe atopic dermatitis and uncontrolled severe asthma in patients aged 12 years and older. A new autoinjector formulation (200 mg in 1.14 mL and 300… | Nov 2022 | Recommended | input received Asthma Australia |
| baricitinib Initial and continuing treatment of adults with severe atopic dermatitis who have failed to achieve an adequate response to topical corticosteroids and/or… | Jul 2021 | Not recommended | 13 individuals Eczema Support Australia · Anaphylaxis Australia · Both Eczema Support Australia |
| upadacitinib Initial and continuing treatment of adults and adolescents aged 12 years or older with severe atopic dermatitis inadequately controlled on topical therapies. | Jul 2021 | Recommended | 10 individuals Eczema Association · Eczema Support Australia · Anaphylaxis Australia · Both Eczema Support Australia |
| dupilumab Treatment of chronic severe atopic dermatitis in adult patients with inadequate response to topical therapies. | Mar 2020 | Recommended with restriction | 323 individuals Anaphylaxis Australia · Eczema Association · Eczema Support Australia |
| crisaborole Mild to moderate atopic dermatitis in patients aged at least 2 years who have failed to achieve satisfactory disease control with, are contraindicated or… | Nov 2020 | Not recommended | 3 individuals |
| dupilumab Treatment of patients aged 12 years and older with severe atopic dermatitis who are inadequately controlled on topical therapies. | Nov 2020 | Noted | 71 individuals |
| dupilumab Treatment of moderate-to-severe atopic dermatitis in adult patients who are inadequately controlled on topical therapies. | Jul 2019 | Not recommended | 159 individuals |
| dupilumab Treatment of adults with severe atopic dermatitis who have had an inadequate response or intolerance to cyclosporin A, or for whom cyclosporin A is… | Jul 2018 | Not recommended | 54 individuals |
| crisaborole Treatment of mild to moderate atopic dermatitis in patients at least 2 years old who are contraindicated, have failed to achieve satisfactory disease control,… | Nov 2018 | Not recommended | input received Eczema Association |
| pimecrolimus Treatment of facial or eyelid atopic dermatitis in patients aged at least 3 months with contraindications to topical corticosteroids, and short-term (up to 3… | Jul 2006 | Recommended with restriction | no section in document |
| pimecrolimus Extension of PBS listing to include treatment of facial or eyelid atopic dermatitis in patients aged at least 3 months (including adults over 18 years) who are… | Jul 2006 | Recommended with restriction | no section in document |
Who spoke
Eczema Support Australia · Anaphylaxis Australia · Eczema Association · National Allergy Council · Both Eczema Support Australia · Asthma Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 20 of 21 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.